share_log

Vivos Therapeutics | EFFECT: Others

Vivos Therapeutics | EFFECT: Others

Vivos Therapeutics | EFFECT：其他
美股sec公告 ·  04/29 06:14
Moomoo AI 已提取核心信息
Vivos Therapeutics, Inc., a company listed in the United States, has achieved a significant milestone with the Securities and Exchange Commission (SEC) declaring its Form S-1 effective as of April 26, 2024, at 4:30 P.M. The Form S-1 is a registration statement that companies must file with the SEC before they can proceed with the sale of securities to the public. The effectiveness of this form indicates that Vivos Therapeutics has met all the regulatory requirements set forth by the SEC, paving the way for a potential public offering or other securities-related activities.
Vivos Therapeutics, Inc., a company listed in the United States, has achieved a significant milestone with the Securities and Exchange Commission (SEC) declaring its Form S-1 effective as of April 26, 2024, at 4:30 P.M. The Form S-1 is a registration statement that companies must file with the SEC before they can proceed with the sale of securities to the public. The effectiveness of this form indicates that Vivos Therapeutics has met all the regulatory requirements set forth by the SEC, paving the way for a potential public offering or other securities-related activities.
在美国上市的公司Vivos Therapeutics, Inc. 取得了重要的里程碑，美国证券交易委员会（SEC）宣布其S-1表格自2024年4月26日下午 4:30 起生效。S-1表格是公司在继续向公众出售证券之前必须向美国证券交易委员会提交的注册声明。该表格的有效性表明，Vivos Therapeutics已满足美国证券交易委员会规定的所有监管要求，为潜在的公开募股或其他证券相关活动铺平了道路。
在美国上市的公司Vivos Therapeutics, Inc. 取得了重要的里程碑，美国证券交易委员会（SEC）宣布其S-1表格自2024年4月26日下午 4:30 起生效。S-1表格是公司在继续向公众出售证券之前必须向美国证券交易委员会提交的注册声明。该表格的有效性表明，Vivos Therapeutics已满足美国证券交易委员会规定的所有监管要求，为潜在的公开募股或其他证券相关活动铺平了道路。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息